OpenEvidence — the clinical AI search platform used daily by more than 40% of US physicians across 10,000 hospitals, processing approximately 18 million clinical consultations in December 2025 alone — has withdrawn its app from the UK and European markets.
The withdrawal, reported by HIStalk on 28 April 2026 and confirmed by multiple sources including DistilledPost and Telecare Aware, cites regulatory uncertainty surrounding the EU Artificial Intelligence Act and its implications for AI tools that influence clinical decision-making. The UK, while not directly subject to EU legislation, has been tracking the AI Act closely without establishing equivalent binding legislation — leaving companies uncertain about the legal basis for deploying high-risk medical AI.
For a company valued at $12 billion with approximately $700 million in total funding from GV, Sequoia, NVIDIA, Kleiner Perkins, and Mayo Clinic, that regulatory ambiguity is apparently sufficient to make European market entry unattractive relative to the settled US environment.
What UK and EU Clinicians Have Lost
OpenEvidence is not just another AI chatbot. It is a specialised medical search engine trained exclusively on peer-reviewed medical literature — not the broader internet. It has formal partnerships with the New England Journal of Medicine and the American Medical Association. It was embedded into Mount Sinai's Epic EHR in March 2026 — placing AI clinical decision support inside the physician's primary workflow. It reached $100 million in annualised revenue by January 2026, proving the commercial viability of free, ad-funded clinical AI at scale.
European clinicians who had been using OpenEvidence — or planning to adopt it — now need alternatives. The search intent is clear and immediate: "What can I use instead?"
Who Fills the Gap: A Practical Comparison
The European clinical AI search market is not empty. Several tools are already positioned — each with different strengths, different guideline coverage, and different trust models.
For UK Clinicians Needing NICE/CKS/BNF/SIGN Answers
iatroX. Free. UKCA-marked, MHRA-registered Class I medical device. Ask iatroX retrieves and synthesises NICE guidelines, CKS summaries, peer-reviewed literature, and SmPC data — the reference standards UK clinicians actually use in daily practice. Also includes 15+ adaptive exam Q-banks (PLAB, UKMLA, MRCP, MRCGP AKT, MRCEM, PSA, MSRA — free; specialist diplomas £99/year), 80+ clinical calculators, and CPD tools. The only platform combining clinical AI, exam preparation, calculators, and CPD in a single MHRA-registered device.
Medwise AI. UK enterprise clinical AI with NHS Trust deployments. Integrates local Trust policies and formularies alongside national guidelines. The HRA has listed a prospective pilot comparing Medwise.ai's AI search engine against manual hospital intranet guideline search — the first study of its kind comparing AI-powered clinical guideline retrieval against the existing NHS workflow. Claims use across 2,000+ NHS organisations. Enterprise licensing — not available to individual clinicians.
Praxis Medicine. New entrant. Founded by Douglas Stark (Voi co-founder), backed by Balderton Capital and Creandum. Breakit reported Praxis raised 70 million SEK in April 2026. Its landing page explicitly lists UK trusted sources: NICE Guidelines, NICE CKS, NHS Digital, and Europe PMC. Praxis has referenced NHS Website Content API access and broader NHS integrations on the NHS England Developer Community — suggesting a UK-first integration path rather than generic LLM search. Early stage, but the founder signal (serial entrepreneur with major VC-backed exits), VC signal (Balderton and Creandum), and source-localisation signal (explicit UK trusted-source grounding) make it credible.
Umbil. UK-focused clinical workflow assistant. Sources answers strictly from NICE, CKS, SIGN, and BNF. Also generates referral letters, discharge summaries, SBAR handovers, and patient consent explanations. Purpose-built tools for daily ward tasks — not just Q&A. Free tier available with student and clinician pricing.
For German/DACH Clinicians Needing AWMF/S3/NVL Guidance
ClariMed. Germany-specific AI guideline search across AWMF, NVL, and S3-style sources. Exhibited at DMEA 2026 with a hospital licensing model. Addresses the same problem as UK tools but for the German clinical evidence ecosystem, which has its own guideline framework entirely separate from NICE.
AMBOSS. Curated clinical evidence model with AI Mode — selected clinical sources, inline citations, transparent limitations, and clinician-built design. Strong across DACH markets and increasingly global. AMBOSS AI Mode represents the curated-content approach: the evidence base is selected and maintained by physician editors, not scraped from the open internet.
For Hospital Buyers Needing Enterprise Governance
UpToDate Expert AI (Wolters Kluwer). GenAI trained exclusively on UpToDate's expert-curated content. Over 7,600 expert clinician authors. Adopted by 70% of largest enterprise health systems. Microsoft partnership (March 2026) embeds UpToDate into Dragon Copilot, Microsoft 365 Copilot, and Microsoft Teams. Now awards CME credits within the AI workflow. Subscription-based — individual ($500+/year) or institutional.
Medwise AI. Enterprise NHS deployment with local policy integration.
How OpenEvidence Compares to the Alternatives
| Dimension | OpenEvidence (withdrawn) | iatroX | Medwise | Praxis | Umbil |
|---|---|---|---|---|---|
| UK availability | Withdrawn | Available | Enterprise only | Early access | Available |
| UK guidelines | No (US-centric) | Yes — NICE/CKS/SmPC | Yes — local + national | Yes — NICE/CKS/NHS | Yes — NICE/CKS/SIGN/BNF |
| Price | Free (ad-funded) | Free (core) | Enterprise | TBC | Free tier |
| Regulatory | None (UK) | MHRA-registered | N/A | N/A | N/A |
| Exam prep | No | 15+ Q-banks | No | No | Student tools |
| Calculators | No | 80+ | No | No | No |
| EHR integration | Epic (US only) | No | NHS Trust | NHS API (planned) | No |
The Deeper Signal
OpenEvidence's withdrawal is not just one company leaving one market. It is a data point about the relationship between regulatory ambiguity and clinical AI deployment. A company with $700 million in funding, clinical validation from 18 million monthly consultations, and the strongest US clinician adoption in the category concluded that European regulatory uncertainty is too great to justify entry.
Whether this pattern repeats — with other US clinical AI tools declining to enter European markets — depends on whether UK and EU regulators clarify the rules. The MHRA's National Commission is developing recommendations. The EU AI Act's high-risk classification framework is being implemented. Until those frameworks settle, European clinicians will rely on Europe-native tools that have already navigated their local regulatory environments.
iatroX has done exactly this. MHRA-registered, UKCA-marked, purpose-built for UK clinical practice. Available now. Free.
Try Ask iatroX — the UK-native clinical AI that OpenEvidence's withdrawal left room for →